Sparks commentary

Healthcare

Sparks

Evaxion (Nasdaq: EVAX) commences Phase II trial extension
Published by Arron Aatkar, PhD

Evaxion has announced that the first patient has been dosed in its one-year extension of the ongoing Phase II trial, which is assessing EVX-01, its personalised cancer vaccine designed by Evaxion’s AI-Immunology platform, in patients with advanced melanoma. This extension should create a more comprehensive data package for the candidate, providing insights into the durability of immune and clinical responses up to three years. Management noted that the trial remains on track for the two-year data readout in H225.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free